| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH |
|
|
|
|||||||
|
|||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Articles in PresS, published online ahead of print September 5, 2002
Am J Physiol Regu Physiol, 10.1152/ajpregu.00324.2002
Submitted on June 4, 2002
Accepted on August 29, 2002
1 Department of Physiology, The University of Melbourne, Melbourne, Victoria, Australia
2 Animal Science, Charles Sturt University, School of Agriculture, Wagga Wagga, New South Wales, Australia
* To whom correspondence should be addressed. E-mail: gsl{at}unimelb.edu.au.
Potential treatments for skeletal muscle wasting and weakness ideally possess both anabolic and ergogenic properties. Although the ß2-adrenoceptor agonist clenbuterol has well-characterised effects on skeletal muscle, less is known about the therapeutic potential of the related ß2-adrenoceptor agonist, fenoterol. We administered an equimolar dose of either clenbuterol or fenoterol to rats for 4 weeks to compare their effects on skeletal muscle and tested the hypothesis that fenoterol would produce more powerful anabolic and ergogenic effects. Clenbuterol treatment increased fiber cross sectional area (CSA) by 6% and maximal isometric force (Po) by 20% in extensor digitorum longus (EDL) muscles, whereas fiber CSA in soleus muscles decreased by 3% and Po was unchanged, compared with untreated controls. In the EDL muscles, fenoterol treatment increased fiber CSA by 20% and increased Po by 12% above values achieved following clenbuterol treatment. Soleus muscles of fenoterol-treated rats exhibited a 13% increase in fiber CSA and a 17% increase in Po above that of clenbuterol-treated rats. These data indicate that fenoterol has greater effects on the functional properties of rat skeletal muscles than clenbuterol.
This article has been cited by other articles:
|
|
 |
|
  J. G. Ryall, J. D. Schertzer, T. M. Alabakis, S. M. Gehrig, D. R. Plant, and G. S. Lynch Intramuscular {beta}2-agonist administration enhances early regeneration and functional repair in rat skeletal muscle after myotoxic injury J Appl Physiol, July 1, 2008; 105(1): 165 - 172. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. S. Lynch and J. G. Ryall Role of {beta}-Adrenoceptor Signaling in Skeletal Muscle: Implications for Muscle Wasting and Disease Physiol Rev, April 1, 2008; 88(2): 729 - 767. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Beitzel, M. N. Sillence, and G. S. Lynch beta-Adrenoceptor signaling in regenerating skeletal muscle after beta-agonist administration Am J Physiol Endocrinol Metab, October 1, 2007; 293(4): E932 - E940. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. G. Ryall, J. D. Schertzer, and G. S. Lynch Attenuation of Age-Related Muscle Wasting and Weakness in Rats After Formoterol Treatment: Therapeutic Implications for Sarcopenia J. Gerontol. A Biol. Sci. Med. Sci., August 1, 2007; 62(8): 813 - 823. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. O. Kline, F. J. Panaro, H. Yang, and S. C. Bodine Rapamycin inhibits the growth and muscle-sparing effects of clenbuterol J Appl Physiol, February 1, 2007; 102(2): 740 - 747. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. G. Burniston, L.-B. Tan, and D. F. Goldspink Relative myotoxic and haemodynamic effects of the {beta}-agonists fenoterol and clenbuterol measured in conscious unrestrained rats Exp Physiol, November 1, 2006; 91(6): 1041 - 1049. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A.-M. Axell, H. E. MacLean, D. R. Plant, L. J. Harcourt, J. A. Davis, M. Jimenez, D. J. Handelsman, G. S. Lynch, and J. D. Zajac Continuous testosterone administration prevents skeletal muscle atrophy and enhances resistance to fatigue in orchidectomized male mice Am J Physiol Endocrinol Metab, September 1, 2006; 291(3): E506 - E516. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Gregorevic, J. G. Ryall, D. R. Plant, M. N. Sillence, and G. S. Lynch Chronic {beta}-agonist administration affects cardiac function of adult but not old rats, independent of {beta}-adrenoceptor density Am J Physiol Heart Circ Physiol, July 1, 2005; 289(1): H344 - H349. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Busquets, M. T. Figueras, G. Fuster, V. Almendro, R. Moore-Carrasco, E. Ametller, J. M. Argiles, and F. J. Lopez-Soriano Anticachectic Effects of Formoterol: A Drug for Potential Treatment of Muscle Wasting Cancer Res., September 15, 2004; 64(18): 6725 - 6731. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Beitzel, P. Gregorevic, J. G. Ryall, D. R. Plant, M. N. Sillence, and G. S. Lynch {beta}2-Adrenoceptor agonist fenoterol enhances functional repair of regenerating rat skeletal muscle after injury J Appl Physiol, April 1, 2004; 96(4): 1385 - 1392. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. G. Ryall, D. R. Plant, P. Gregorevic, M. N. Sillence, and G. S. Lynch {beta}2-Agonist administration reverses muscle wasting and improves muscle function in aged rats J. Physiol., February 15, 2004; 555(1): 175 - 188. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH |
| Visit Other APS Journals Online |
